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Abstract 
 
Following marrow transplantation in both patients and animals, cells containing donor 
nuclei have been detected in a variety of nonhematopoietic tissue. Whether this 
phenomenon represents transdifferentiation of marrow-derived cells, infiltration of blood 
cells, or cell fusion is still controversial. In muscle, where cell fusion occurs during 
normal myogenesis, fusion of marrow-derived cells with resident myotubes is a likely 
explanation. We tested eight subpopulations of human bone marrow for their ability to 
fuse with mouse C2C12 myoblast cells. Relatively high fusion efficiency was observed 
with marrow stromal cells whereas hematopoietic cells, including populations enriched 
for stem cells, progenitor cells and monocytes were refractory to fusion. Mouse myotubes 
containing human nuclei also contained transcripts for human muscle specific genes. 
Injection in vivo of human stromal cells expressing green fluorescent protein (GFP) into 
the regenerating tibialis anterior muscle of NOD/SCID β2m-/- mice resulted in 
regenerating mouse muscle fibers expressing GFP. These data suggest that marrow-
derived cells contribute to myogenesis through fusion and that stromal cells are better 
fusion partners than hematopoietic cells.  
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Introduction 
 
Recent reports suggest that bone marrow derived cells can be detected in regenerated 
muscle tissue of mice 
1-4. In addition, bone marrow transplantation in the mdx mouse, a 
model for Duchenne muscular dystrophy (DMD), resulted in the detection of donor cell-
derived dystrophin in affected muscle fibers 
5,6. The presence of donor cells in muscle 
fibers was also observed in a DMD patient who received an allogeneic marrow 
transplantation at one year of age 
7. However in both the mdx mouse and the DMD 
patient the contribution of donor cells to affected muscle was very low and did not impact 
muscle function 
7,8. Whether this low frequency event represents transdifferentiation of 
marrow stem cells into muscle or rare fusion events remains controversial
9-11. 
 
Resolving this controversy is critical for understanding the real potential and limitations 
of marrow transplantation. In addition, understanding how marrow cells contribute, even 
as rare events, to myogenesis is an important step towards developing strategies to 
increase the frequency of these events. We hypothesized that, regardless of the 
mechanism, bone marrow derived cells could be therapeutically valuable if a higher 
frequency of donor cell contribution to myogenesis could be achieved. This concept is 
supported by studies in which wild-type mesoangioblast cells were shown to rescue the 
α-sarcoglycan null dystrophic mice through myogenic fusion
12. To identify human 
marrow cells with myogenic fusion potential we investigated the ability of human cells to 
contribute to myogenesis using first a xenogeneic in vitro model combining mouse 
C2C12 myoblasts with various subsets of human marrow cells, and second using an in 
vivo regeneration model. 
 
C2C12 cells represent an early stage of muscle differentiation. Depending on the culture 
conditions, they can either proliferate as myoblasts or differentiate into myotubes 
13. 
Previous studies have shown that co-culturing C2C12 cells with dermal fibroblasts 
resulted in cell fusion and the subsequent correction of the dysgenic membrane in 
regenerating muscle
14-16. The myogenic potential of neural stem cells was also 
demonstrated by coculture with C2C12 cells 
17,18. In this report we co-cultured human 
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hematopoietic and non-hematopoietic bone marrow cells with C2C12 and found that 
stromal cells have a significantly greater potential to contribute to myotube formation 
than enriched populations of hematopoietic progenitor cells, and that this contribution is 
due to cell fusion. Human stromal cells also contributed to regenerating muscle in vivo in 
the NOD/SCID β2m-/- mouse. 
 
Material and Methods 
 
Human cell preparations. Human CD34+ cells from cadaveric marrow were provided 
by the Cellular Therapy Laboratory, Fred Hutchinson Cancer Research Center. Flow 
sorting was used to prepare CD34+ and CD34+/38- populations, both greater than 95% 
pure. A more differentiated CD33+ population was expanded from the CD34+ cells by 
culturing for 6 days in RPMI with 10 ng/ml IL-3, IL-6, G-CSF, and SCF. More mature 
CD14+ cells were sorted from peripheral blood mononuclear cells obtained from healthy 
donors. Long term marrow cultures (LTC) and mesenchymal stem cells (MSC) were 
prepared from normal donor marrow as described previously
19,20. Both the LTC and MSC 
populations were depleted of CD45+ cells prior to co-culturing with C2C12 myoblasts. 
All samples of human blood and bone marrow were obtained from normal donors after 
informed consent as required by the FHCRC Institutional Review Board. 
 
Fusion assay. 2,500 stromal cells/cm
2 or 125,000 hematopoietic cells/cm
2 from human 
marrow preparations were co-cultured with 2,500 C2C12 myoblasts /cm
2 for four days in 
DMEM 10 % FBS, then cultured for two additional days in DMEM with 10 µg/ml 
insulin and transferrin to promote myotube formation. The cultures were fixed in 4% 
paraformaldehyde and stained with a mouse anti-human nuclei IgG1 monoclonal 
antibody (Chemicon) and the anti-sarcomeric myosin heavy chain IgG2b monoclonal 
antibody MF-20 (a gift from Dr. Hauschka). The cells were visualized with appropriate 
Alexa-fluor conjugated goat anti-mouse IgG1 and IgG2b secondary antibodies 
(Molecular Probes). Total cell nuclei were stained with DAPI. The slides were analyzed 
using a Nikon eclipse TE300 microscope. Images were captured by a MicroMAX digital 
camera (Princeton Instruments, Inc). 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From    5 
 
RT-PCR. Total RNA was isolated from cell cultures using RNeasy Mini kit (Qiagen) 
and RT-PCR were performed using superscript one step RT-PCR system (Invitrogen) 
with human specific MYH-2 primers (forward, 5’-ctgctgaaggagagggagct-3’; reverse, 5’-
tgattagctggtcacacctt-3’) and actin primers (forward, 5'-agagctacgagctgcctgacggcc-3'; 
reverse, 5'-agtgatctccttctgcatcctgtcc-3'). The PCR products were resolved by 
electrophoresis on a 1.5 % agarose gel and visualized by ethidium bromide staining. 
 
Lentiviral infection. The pseudotyped HIV-1–derived vector VSV-
G/pRRLSincPPThpakGFPwpre was provided by Dr Hans-Peter Kiem (FHCRC). 
Multiplicities of infection (MOIs) of the virus were measured on proliferating HT1080 
cells. The MSC cells were cultured with the GFP-encoded virus at MOI of 10 overnight, 
with fresh media added the next day. GFP positive MSC cells were sorted by FACS 
Vantage SE Cell Sorters (Becton Dickinson) and injected into the tibialis anterior muscle 
of mice. 
 
Cardiotoxin injury and cell injection. NOD/SCID β2m-/- mice 8-10 weeks of age were 
anesthetized with Avertin (0.018-0.022 ml/g body weight), followed by muscle injury to 
the tibialis anterior (TA) by injection of 40µl cardiotoxin (20 µM in PBS). After 24 
hours, 3x10
5 human MSC cells were injected into the injured TA muscle. Seven days 
after injection mice were euthanized by pentobarbital overdose, the TA muscles were 
harvested and processed for frozen sections. 
 
Immunohistochemistry. The TA muscles were frozen in OCT embedding medium and 
sectioned as 6 µm longitudinal sections. The sections were fixed in 4% paraformaldehyde 
and incubated with anti human nuclei antibody (1:250) overnight at 4
oC followed by 
alexa fluor488 goat anti mouse IgG1 secondary antibody (Molecular Probes). The 
myofibers were revealed by rhodamine phalloidin staining (Molecular Probes). The 
images were captured by Deltavision SA3.1 Wide-field Deconvolution Microscope 
(Applied Precision, Inc). For the GFP fusion study, the TA images were captured from 
frozen sections by Nikon Eclipse E800 microscopy and followed by H&E staining of the 
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same sections. To reconstruct a 3D image of GFP+ regenerating TA muscle fibers, a 
stack of 44 1µm sections of a frozen TA muscle were acquired as green and red two 
channel images by a Leica TCS SP confocal microscope and imported into MetaMorph 
software as a series of TIF files. A 3D reconstruction was created by Volocity software 
and used to generate a Quicktime movie showing a 180-degree horizontal rotation of the 
stack. This short video is available as supplemental data. 
 
Results 
 
Detection of human marrow cell contribution to myotubes in an in vitro myogenesis 
model. In an effort to better understand the contribution of bone marrow-derived cells to 
muscle repair, we established a xenogeneic in vitro cell culture model in which different 
populations of human marrow cells were tested for their ability to fuse with mouse 
myotubes. In this model, human marrow derived cells were co-cultured with C2C12 for 
four days under proliferative conditions then switched to differentiation conditions for an 
additional two days. Figure 1 provides an example of how human nuclei in the myotubes 
were detected. Multinucleated myotubes were revealed by the presence of sarcomeric 
myosin heavy chain (Fig 1A). Human nuclei are unequivocally identified by staining 
with an anti-human nuclei monoclonal antibody (Fig 1B), while the numerous mouse 
nuclei present in this field as shown by DAPI staining (Fig 1D) are negative. The 
contribution of human marrow cells to the myotubes was determined by the presence of 
human nuclei in the myotubes, which were easily distinguished from those outside the 
myotubes by spatial correlation of human nuclei staining with nuclear spaces revealed by 
MF20 staining (Fig 1A and 1C). 
 
The results in Figure 1 showed that co-culture of human LTC cells with the C2C12 
mouse myoblasts resulted in the contribution of human nuclei to mouse myotubes. The 
results were further confirmed by confocal microscopy. To further identify the cells in 
LTC responsible for myogenic fusion, we isolated stromal cells by sorting out CD45+ 
hematopoietic cells. The stromal cells showed the same fusion frequency with C2C12 as 
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LTC cells, indicating the stromal cells in the LTC are the major cell population to fuse 
with myoblasts. 
 
 
 
Figure 1. Triple staining to identify cell fusion. 5,000 human marrow cells from a long-term culture were 
co-cultured with 5,000 C2C12 cells for 4 days under conditions that favored proliferation. The cultures were 
then switched to differentiation media for 2 days to induce myogenic fusion. Myotubes were revealed by 
sarcomeric myosin heavy chain monoclonal antibody MF20 (A). Human nuclei were detected by antibody 
specific to human nuclei (B). The fusion of human marrow cells (arrow head) with myotubes was detected by 
correlating the human nuclei with nuclear spaces in the myotube (C). In contrast, unfused stromal cells (arrow) 
did not align with the myotube nuclear space. Total cell nuclei in the culture were stained with DAPI (D, 
blue). The same results were observed from CD45 depleted primary stromal cells and mesenchymal stem 
cells. However, human stromal cell lines HS-5 (E) and HS-27a (F) failed to fuse with C2C12 in co-culture. 
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Recently mesenchymal stem cells (MSC) from marrow were reported to give rise to 
adipocytes, chondrocytes, osteocytes, and stromal cells under different culture conditions 
20-22. Given their pleiotropic potential, we tested the ability of MSC to fuse with C2C12. 
Though the stromal cells generated in LTC media and MSC media are morphologically 
different and MSC cells proliferated more than LTC cells, a similar number of fusion 
events were observed (Table 1). To determine whether fusion was a common feature of 
adherent stromal cells we tested two immortalized stromal cell lines derived from human 
LTC. One line, designated HS-5, has small fibroblast like cells that secrete many 
cytokines. The other, HS-27A, has large cells that support cobble-stone area formation 
23,24. Both HS-5 and HS-27A failed to fuse with myotubes (Fig 1E and F), suggesting that 
only specific subpopulations of marrow stromal cells have the potential to fuse. 
 
Table 1. Fusion events between human cells and mouse C2C12 myoblasts.*  
Human Cell  
Populations 
Events/ Number of  
Cells Tested 
Frequency 
 
Hematopoietic Compartment 
CD34+/38-  0/  45,000     0 
CD34+ 1/  250,000  .000004 
CD33+  0/ 250,000     0 
CD14+  0/ 250,000     0 
 
Stromal Compartment 
LTC 145/    5,000  .029 
MSC 190/    5,000  .038 
HS-5  0/  5,000     0 
HS-27a  0/  5,000     0 
    
Control Cell 
HFF  4/  5,000                    .0008 
    
 * Each myotube containing one or more human nucleus was counted as one event. 
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Given that both LTC and MSC populations are reported to have stem cell potential, we 
considered whether the C2C12 co-culture conditions actually induced myogenic 
differentiation of these cells rather than cell fusion. We hypothesized that fusion would 
require cell-cell contact whereas ‘transdifferentiation’ would not. To address this the 
MSC and C2C12 were initially cultured separately, then added together when myogenic 
fusion was induced. After two days, no human nuclei containing myotubes were 
observed. In a separate set of experiments we tested whether C2C12 can induce a 
myogenic program in MSC through secreted molecules. In this case MSC and C2C12 
were cultured in transwells to avoid direct cell-cell contact but allow an exchange of 
culture media throughout the 6 days of culture. No myosin heavy chain positive staining 
cells or myotubes were observed in the MSC culture, while normal myogenesis occurred 
in the chamber containing the C2C12 (data not shown). Therefore, stromal contribution 
to myotubes requires contact with C2C12 myoblasts. 
 
Lack of myogenic fusion with hematopoietic cells. We next assessed the ability of 
various hematopoietic cells to fuse with C2C12. Four populations of hematopoietic cells 
were studied: CD34+CD38- population that is enriched for stem cells, CD34+ population 
containing hematopoietic progenitor cells, CD33+ relatively mature myeloid progenitor 
cells, and CD14+ monocytes. In these experiments 250,000 cells of each type were co-
cultured with C2C12, and only one myogenic fusion event was detected. These studies 
are summarized in Table 1. These negative results raised the concern that the C2C12 
culture conditions may adversely affect hematopoietic cells and thereby prevent their 
fusion. To address this concern we repeated the experiments using LTC media to support 
hematopoietic cells during the first 4 days of culture. Under these conditions myotube 
formation still occurred and more human cells were retained, however there were no 
detectable fusion events (data not shown). Therefore we conclude that hematopoietic 
cells are refractory to myogenic fusion. 
 
Fusion induces human myosin heavy chain expression. The presence of human nuclei 
in mouse myotubes raised the question as to whether any human muscle specific genes 
were transcribed . In the in vitro myogenesis model, we observed that most “hybrid 
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Figure 2. Fusion induces human myosin heavy chain expression. RT-PCR of the cultured 
cells shows elevated expressions of human skeletal myosin heavy chain IIa (MyH-2a) in 
co-cultures of stromal cells and C2C12 cells. Lane 1 is from human skeletal muscle cells and 
serves as a positive control; lane 2, C2C12 cells alone; lane 3, human MSC alone; lane 4, 
co-culture of MSC and C2C12; lane 5, human LTC alone; and lane 6, co-culture of human 
LTC and C2C12. Actin was used as a loading control. 
myotubes” were positive for multiple human nuclei. However the staining intensity of 
these nuclei was not consistent, but rather appeared as a decreasing gradient from one 
brightly stained nucleus. This observation suggested that the human nuclear proteins from 
one nucleus were transported to neighboring mouse nuclei. Transportation of proteins 
among nuclei in myotubes has been described previously 
15. We hypothesized that mouse 
muscle-specific transcription factors may translocate in a similar fashion to human nuclei 
and turn on transcription of human muscle-specific genes. To measure the human muscle 
gene expression, total RNA was isolated from C2C12, LTC, MSC, and co-cultures of 
LTC and MSC with C2C12. RT-PCR was performed using human specific primers. 
Among several myosin heavy chain genes tested, we detected elevated myosin heavy 
chain IIa gene expression in the co-cultures, indicating that muscle specific genes in 
stromal cell can be turned on through myogenic fusion (Fig 2). 
 
 
Human stomal cells delivers green florescent protein to the regenerating TA muscle 
in vivo. Our cell culture experiments indicated that bone marrow stomal cells are capable 
of fusing with myotubes. To test whether the MSC cells can fuse with skeletal muscle 
fibers undergoing repair after injury in vivo, cardiotoxin was injected into the tibialis 
anterior of NOD/SCID β2m-/- mice. Twenty-four hours later, human MSC cells were 
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injected into the cardiotoxin-injured muscles. TA muscles were examined after 7 days for 
the presence of human nuclei in skeletal myofibers by immunofluorescent staining with 
anti human nuclei antibody in combination with Rhodamine phalloidin staining for 
muscle fibers. Data indicate that 0.44% of injected human cells was incorporated into 
myotubes. One example of a human nucleus inside a myotube is shown in Figures 3A-C. 
In comparison to uniform staining of the intact human nuclei shown in Figure 1, the 
staining of the nucleus in 3B has a stippled pattern due to the fact that this image 
represents a section through the nucleus. 
Figure 3.  Fusion of human MSC cells in regenerating mouse TA muscle. The TA muscle of 
the NOD/SCID β2m-/- mouse was damaged by cardiotoxin injection followed 24 hours later by 
injection of  MSC . The regenerating TA muscles were evaluated seven days later. 
Immunoflorescence staining of regenerating  TA muscle showed the presence of human nuclei in  
muscle fibers;  A) Red  rhodamine phalloidin staining  of mouse TA muscle with blue DAPI 
nuclear staining;  B) Human nuclear staining (green) with anti- human nuclear antibody; 
C) composite of A and B.  H&E staining of a frozen section of regenerating TA muscle (D) and 
fluorescence microscopy of the same section showing a GFP expressing fiber (E). Two GFP+ 
fibers, each longer than 100um, are shown in a snapshot of a 3D projection of a stack of 44 green 
and red two-channel images of a regenerating TA muscle (F). A rotating video of this section is 
available as supplemental data. 
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To verify the fusion of human MSC cells with mouse muscle, GFP expressing MSC were 
prepared by lentiviral infection. The GFP positive MSC cells were then injected into the 
regenerating TA muscle. After a week, the TA muscles were examined for the presence 
of green fibers. No GFP signals were observed in PBS-injected control TA muscle. 
However GFP positive fibers were present in GFP-MSC injected muscle (Fig 3D). 
Hematoxylin and eosin staining of the same section suggested that the GFP signals 
originated from regenerating TA myofibers but were absent in undamaged muscles 
(arrows, Fig 3D and E). The presence of GFP+ myofibers was confirmed by confocal 
microscopy (Fig 3F and supplemental data). In these experiments more than 100 6µm 
longitudinal sections were cut per TA muscle, and one section per every 20 sections was 
analyzed for GFP expressing fibers. The average number of myotubes per section was 
4,396 and had on average one GFP+ fiber. These data indicate that 0.023% of total TA 
muscle fibers were GFP+. 
 
Discussion 
 
The detection of bone marrow derived cells in muscle as well as many other tissues has 
generated considerable enthusiasm for rethinking the differentiative potential of adult 
stem cells and their possible role for various tissue replacement therapies. Though there 
are multiple reports of marrow-derived cells in non-hematopoietic tissue, the significance 
of the findings remains unclear due to the low frequency of these events, as does an 
understanding of the mechanism responsible for the observation.  
 
In bone marrow transplant recipients, donor blood cells will be present in every tissue in 
the body. Therefore, when searching for donor cell contribution to recipient tissue care 
must be taken to control for blood derived lymphocytes and macrophages. This is a 
particular issue for in vivo experiments in which tissue damage is used to trigger 
regeneration, resulting in recruitment of blood, ultimately marrow-derived cells to the 
damaged area. Donor cell contribution to regeneration can, at least theoretically, take 
several forms: macrophages can scavenge dead cells and secrete factors that favor 
endogenous regeneration, lymphocytes may also produce beneficial factors, totipotent 
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stem cells may differentiate into the needed tissue, or other undefined populations may 
fuse with endogenous regenerating cells. Distinguishing between these possibilities is 
critical for understanding the real potential of adult stem cells and shaping future research 
efforts accordingly. 
 
In the current study, we first used differentiating mouse C2C12 myoblasts as an in vitro 
model of myogenesis to test the capability of different human bone marrow cells to fuse 
with myotubes. We found that marrow stromal cells cultured either as LTC or MSC, but 
not hematopoietic cells, fuse with C2C12 myoblasts. The fusion required cell-cell 
contact, and resulted in the expression of human myosin heavy chain. 
 
We tested four populations of human cells in the hematopoietic lineage, CD34+CD38- an 
enriched stem cell population, CD34+ enriched for stem/ progenitor cells, CD33+ 
committed myeloid progenitor cells, and CD14+ monocytes. With the exception of one 
rare event, these cells were not able to fuse with C2C12 cells and contribute to myotubes. 
The one exception was in the CD34+ cell population which could, at least theoretically, 
be attributed to stromal precursors known to express CD34
25. The lack of hematopoietic 
fusion with C2C12 was not due to the culture conditions: experiments were also 
conducted using culture media that supported the survival of hematopoietic cells, yet no 
fusion occurred between hematopoietic cells and myotubes. Our failure to demonstrate a 
contribution of hematopoietic cells to myogenesis in vitro is consistent with recent 
publications that showed only rare hematopoietic cell contribution to myogenesis in vivo, 
in both the cardio toxin injury and mdx mouse models
26,27. These reports question the 
efficacy of hematopoietic stem cell transplantation for the treatment of muscle diseases. 
 
The non-hematopoietic cells in the marrow, or stromal cells, are a heterogenous 
population. They provide the microenvironmental (ME) niche for stem cells and their 
progeny. The ME can be approximated in vitro in primary long-term cultures (LTC) 
established from marrow aspirates. More recent studies have described culture conditions 
that allow the outgrowth of stromal cells reported to have stem cell potential. These are 
termed mesenchymal stem cells (MSC). In our C2C12 fusion study, cells from both LTC 
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and MSC cultures were able to fuse with C2C12. In addition, an increased level of human 
myosin heavy chain expression in the C2C12 co-cultures indicated that both LTC and 
MSC were able to initiate a myogenic program. Importantly, immortalized human 
stromal cell lines, HS5 and HS27a failed to fuse with C2C12, suggesting that fusion was 
not necessarily promiscuous among adherent, fibroblastic cells. Although fusion of 
fibroblasts with myogenic cells in vitro has been reported previously
15,16, and may 
suggest little in the way of specificity for fusion partners, our results suggest otherwise. 
We tested nine populations of human cells and found significant differences among them 
in terms of fusion frequencies (Table 1). Considering the heterogeneity of LTC and MSC 
cultures further studies are needed to identify the subpopulation of cells in these cultures 
capable of fusion. 
 
Taken together these data indicate that marrow derived cells in LTC and MSC cultures 
can fuse with relatively high efficiency to myoblasts in vitro. Given the ease with which 
LTC or MSC can be expanded in vitro and transduced 
28,29, they appear to be an attractive 
source of cells for fusion in vivo. To test this we injected GFP labeled MSC into 
damaged mouse TA muscles and showed regenerating muscle fibers expressing GFP, 
indicating a contribution of human cells to regenerating muscle. The frequency of fusion 
events was low, comparable to that reported for the detection of donor cells after stem 
cell transplantation. This suggests therefore that the detection of “donor” derived cells 
following transplantation can be as easily attributed to fusion as to transdifferentiation. 
Whether such fusion events could eventually prove therapeutic is unclear. Much work is 
needed to establish the in vivo relevance of this observation; paramount among this work 
is the development of ways to deliver therapeutic cell preparations to target tissue and to 
increase the frequency of the fusion events. Understanding the molecular mechanisms 
involved in stroma/C2C12 fusion in vitro could provide insights needed to increase the 
fusion efficiency in vivo. 
 
SUPPLEMENTAL MATERIAL IS AVAILABLE ONLINE AT THE TIME OF 
FINAL PUBLICATION ONLY. 
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